Navigation Links
BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its Annual Report
Date:3/19/2012

vity of BEMA Buprenorphine and BNX through 2027, is expected by the end of second quarter 2012.  The allowance of the patent was made by the United States Patent and Trademark Office (USPTO) in February 2012, while the formal granting that triggers this milestone payment typically occurs within 3 months of the allowance.  

"The past fifteen months have been very exciting for BDSI as we have made significant progress in prudently deploying our resources and moving our company forward," said Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI.  "We are very pleased to partner with a company of the caliber of Endo Pharmaceuticals for BEMA Buprenorphine for chronic pain, with whom we are working towards initiation of two Phase 3 studies in the third quarter of this year.  With Endo's added involvement in this development program and experience in pain, we believe the probability of a positive outcome in this program is enhanced.  In addition, BEMA Buprenorphine is extremely complimentary to Endo's already impressive pain franchise and represents the only Schedule 3 opioid in their branded portfolio.  We continue to believe that BEMA Buprenorphine has the potential to achieve peak sales in excess of $500 million." 

According to Dr. Andrew Finn, Executive Vice President of Product Development, "As it relates to BNX, we began 2012 with a meeting with FDA and obtained clear guidance on this program that could lead to an NDA submission in the first half of 2013 and subsequently allow us to enter the rapidly growing market for the treatment of opioid dependence.  BNX has the opportunity to be the first branded transmucosal buprenorphine/naloxone product to compete with Suboxone, which achieved sales in excess of $1.2 billion in 2011 and continues to grow."

2011 Corporate Update

By way of review, the following are key events that occurred at BDSI over the past 15 months:


    SOURCE BioDelivery Sciences International, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
    2. BioDelivery Sciences Announces BEMA Buprenorphine Phase 3 Chronic Pain Study More Than 50% Recruited and on Schedule
    3. BioDelivery Sciences Confirms 505(b)(2) Pathway for BEMA Buprenorphine/Naloxone for Opioid Dependence Following FDA Meeting
    4. BioDelivery Sciences to Present at the 23rd Annual ROTH OC Growth Stock Conference
    5. BioDelivery Sciences Announces Completion of Recruitment in BEMA Buprenorphine Phase 3 Chronic Pain Study
    6. BioDelivery Sciences Provides Update on Status of Modified REMS Program for ONSOLIS
    7. BioDelivery Sciences to Present at the Jeffries Global Healthcare Conference
    8. BioDelivery Sciences Announces Commercial Launch of ONSOLIS in Canada
    9. BioDelivery Sciences Announces Upcoming Presentations at Three Investor Conferences
    10. BioDelivery Sciences Announces Positive Results Supporting BEMA Buprenorphine/Naloxone Formulation for Opioid Dependence
    11. Samuel J. Sears, Jr. Appointed to BioDelivery Sciences Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/29/2014)... 2014 /PRNewswire-iReach/ -- SAM Medical Products Implements Voluntary ... SAM Junctional Tourniquet.  Photo - ... Products announced today that it has begun notifying ... potential issue with a clip used to secure ... of the SAM Junctional Tourniquet (SJT).  The company ...
    (Date:8/29/2014)... PARK, Calif. , Aug. 29, 2014 ... Medical as CEO and member of the Board of ... decades of medical device development and commercialization experience, including ... field. Mr. Engelson previously served as a Partner of ... as President and CEO of two Foundry start-ups. Mr. ...
    (Date:8/29/2014)... 29, 2014 Research and Markets ... Cancer Therapeutics Market & Pipeline Insight 2014" report ... developed to prevent and eradicate the prevalence of cancer ... are confined to low specificity, safety and large number ... for a better solution. It has been discovered that ...
    Breaking Medicine Technology:SAM Medical Products Implements Voluntary Recall of its Accessory (Axilla) Strap for the SAM Junctional Tourniquet. 2Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2
    ... 2011 CRC Health Group, the nation,s largest ... today announced the successful acquisition of North Carolina,s ... Solutions, comprised of two facilities located in Asheville ... program by the U.S. Department of Health and ...
    ... Inc., a leader in medical billing and practice management for ... clients are highly satisfied with its services, according to the ... percent of those surveyed said they would recommend Orion to ... physician groups, laboratories, imaging centers and other healthcare provider clients ...
    Cached Medicine Technology:CRC Health Group Announces Acquisition of North Carolina's Mountain Health Solutions 2Orion HealthCorp Gets High Marks From Clients 2
    (Date:9/1/2014)... 01, 2014 Parties involved in federally-filed ... the litigation’s status conference in September, where issues related ... in the Eastern District of Pennsylvania, Bernstein Liebhard LLP ... conferences posted on the Court’s website, the meeting is ... 10:00 a.m. This is the latest of several Tylenol ...
    (Date:9/1/2014)... 01, 2014 Ontraport , one ... that was developed to automate the small intricacies of ... of Shane Michaels, prompting an investigative review. , ... duty of managing all of the small details involved ... overwhelming,” reports Michaels. “That’s why Ontraport has become so ...
    (Date:9/1/2014)... (PRWEB) September 01, 2014 AttorneyOne.com, a ... all the latest information from the FDA on ... US FDA announced on August 28, that specific lots ... (Class I) as the device may reverse directions ... Synthes Craniomaxillofacial (CMF) Distraction System is an implant used ...
    (Date:9/1/2014)... Nevada (PRWEB) September 01, 2014 Beginning ... to over 3,000 medical professionals and 10,000 consumers for ... is a 5-day gathering of the nation’s top medical ... associated diseases or conditions. The week-long event contains more ... evidence-based scientific instruction available in the pain management field. ...
    (Date:8/31/2014)... 2014 An analysis of 32 studies ... revealed a link between lower levels of Vitamin D ... the August 2014 issue of American Journal ... form of Vitamin D found in blood. , ... D lower than 9 nanograms/milliliter (ng/mL) were twice as ...
    Breaking Medicine News(10 mins):Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4Health News:Ontraport: Review Exposes Automated Platform for Online Marketing Management 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 3Health News:Medical Marijuana Doctor Company Set to Present at Las Vegas Pain Week 2Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 2Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 3Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 4
    ... the Queen Silvia Children,s Hospital has developed a method that ... a CT scan while still obtaining good image quality, reveals ... an advanced form of X-ray examination which generates images that ... the dose of radiation is lowered too far, however, the ...
    ... , MONDAY, April 4 (HealthDay News) -- People with ... new study suggests. It also found that a decrease ... abuse and mood disorders. Researchers analyzed data from nearly ... the U.S. National Epidemiologic Survey of Alcohol and Related Conditions. ...
    ... Eran Shor, working in collaboration with researchers from Stony ... of premature mortality by 63 per cent. Shor reached ... people in 15 (mainly western) countries, over the last ... in spite of expectations that a better health-care system ...
    ... HealthDay Reporter , MONDAY, April 4 (HealthDay News) -- Heavy ... metabolism of alcohol may face a higher risk than others ... a certain genetic variant and drinking roughly three ... markedly increase the risk of "non-cardia gastric cancer," a study ...
    ... 2011) The gender gap among United States Medical ... surgery is shrinking, according to study results published in ... American College of Surgeons . These findings align with ... medical students. The study found a 22 percent ...
    ... Goodwin HealthDay Reporter , MONDAY, April ... use of most medications for treating autism in ... risperidone and aripiprazole that have shown success in ... new study shows. However, anti-psychotics can have ...
    Cached Medicine News:Health News:Safer CT scanning for children developed at the Queen Silvia Children's Hospital 2Health News:Poverty Linked to Anxiety, Mood Disorders 2Health News:Men who lose their jobs at greater risk of dying prematurely 2Health News:Heavy Beer Drinking, Genetics May Raise Risk of Stomach Cancer 2Health News:Heavy Beer Drinking, Genetics May Raise Risk of Stomach Cancer 3Health News:More women medical students select general surgery and continue to close the gender gap 2Health News:Evidence Weak to Support Many Medications for Autism: Study 2Health News:Evidence Weak to Support Many Medications for Autism: Study 3Health News:Evidence Weak to Support Many Medications for Autism: Study 4
    ... West Nile Virus IgG DxSelect is ... West Nile virus in human,serum. In ... Nile Virus,IgM Capture DxSelect, the test ... of meningioencephalitis, as an aid in ...
    ... PachPen uses state-of-the-art waveform analysis ... at a 65MHz rate to ... stores and averages nine measurements ... pen fits comfortably into the ...
    Ambion's barrier tips prevent cross-contamination of samples by means of an aerosol filter. They are RNase- and DNase-free and are ideal for handling RNA, PCR applications, and for working with radio...
    Conducting disposable filter-tips....
    Medicine Products: